This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
To the Editor.
—I would like to accent some of the topics that Ball and Schneider1 address in their article, adding a different emphasis. To accurately compare the cost of items, one must insure that all are equal. The β-blockers discussed in this article are not equivalent with respect to pharmacology, efficacy, safety, or comfort.The pharmacology of betaxolol hydrochloride is different than those of the other compounds. Betaxolol is a cardioselective β-adrenoceptor antagonist. The others are nonselective. The article, due to timing, does not include carteolol hydrochloride. Carteolol is a β1-β2 adrenoceptor antagonist with intrinsic sympathomimetic activity. Carteolol's pharmacokinetics differ, at least after systemic administration.The data analysis assumes a "roughly equivalent ocular hypotensive effect." The ocular hypotensive effect of β1-blockers is not equivalent to those of nonspecific β-blockers, either as an initial therapy or when switching from a nonspecific β-blocker to a
Robin AL. Pitfalls in Comparing the Costs of Various β-Adrenoreceptor Antagonists. Arch Ophthalmol. 1993;111(3):299. doi:10.1001/archopht.1993.01090030017007